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Summary
Autosomal dominant hypercholesterolemia (ADH), one
of the most frequent hereditary disorders, is character-
ized by an isolated elevation of LDL particles that leads
to premature mortality from cardiovascular complica-
tions. It is generally assumed that mutations in theLDLR
and APOB genes account for ADH. We identified one
large French pedigree (HC2) and 12 additional white
families with ADH in which we excluded linkage to the
LDLR and APOB, implicating a new locus we named
“FH3.”A LOD score of 3.13 at a recombination fraction
of 0 was obtained at markers D1S2892 and D1S2722.
We localized the FH3 locus to a 9-cM interval at
1p34.1–p32. We tested four regional markers in another
set of 12 ADH families. Positive LOD scores were ob-
tained in three pedigrees, whereas linkage was excluded
in the others. Heterogeneity tests indicated linkage to
FH3 in ∼27% of these non-LDLR/non-APOB ADH
families and implied a fourth locus. Radiation hybrid
mapping located four candidate genes at 1p34.1-p32,
outside the critical region, showing no identity with
FH3. Our results show that ADH is genetically more
heterogeneous than conventionally accepted.
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Introduction
Autosomal dominant hypercholesterolemia (ADH) is an
inherited disorder of lipid metabolism, characterized by
a selective increase of LDL particles in plasma (type IIa
hyperlipoproteinemia) giving rise to tendon and skin
xanthomas, arcus corneae, and premature mortality
from cardiovascular complications (Goldstein and
Brown 1989). Twenty-five years ago, Goldstein and
Brown (1974) showed that ADH results from defects in
the cell-surface receptor that removes LDL particles from
plasma. They coined the disorder “familial hypercho-
lesterolemia” (FH; MIM 143890). The LDL-particle re-
ceptor is a ubiquitous transmembrane glycoprotein of
839 amino acids that mediates the transport of LDL
particles into cells via endocytosis (Goldstein and Brown
1974). The LDL-particle receptor gene (LDLR) was
cloned by Yamamoto et al. (1984) and mapped to
19p13.1-13.3 by Lindgren (1985), and 1600 mutations
scattered throughout the 45-kb gene have now been re-
ported (Varret et al. 1997a, 1997b, 1998; LDLR Mu-
tation Database). Innerarity et al. (1987) demonstrated
the genetic heterogeneity of ADH by reporting hyper-
cholesterolemic patients with normal LDL-particle re-
ceptor activity and defective apolipoprotein B-100 that
displayed low affinity for its receptor. This new molec-
ular disorder was called “familial ligand-defective apo-
lipoprotein B-100” (FDB; MIM 144010). The APOB
gene spans 43 kb, is divided into 29 exons, and maps
to chromosome 2p23-p24 (Law et al. 1985). To date,
three mutations in the APOB gene associated with ADH
have been reported: the R3500Q mutation is the most
frequent, whereas the R3531C and the R3500W are
relatively rare (Rabe`s et al. 1997). Thus, it convention-
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ally is assumed that only two distinct genetic disorders
account for the ADH phenotype.
The existence of a greater level of genetic heteroge-
neity has never been formulated clearly. However, care-
ful examination of the literature shows that, by different
approaches, a few families have been identified in which
the ADH phenotype was not associated with defects in
the LDLR and APOB genes. Lestavel-Delattre et al.
(1994) studied 41 patients with the ADH phenotype
(plasma LDL-cholesterol level 195th percentile, xantho-
mas, and/or personal or family history of coronary artery
disease) and found normal LDL-particle receptor activity
and normal LDL-particle binding in nine patients who
did not carry the R3500Q mutation in the APOB gene.
Further studies showed that six of these patients carried
a mutation in the LDLR gene, but for the three other
ADH subjects the genetic origin of the disease is pres-
ently unknown (Nissen et al. 1998). These results could
be explained by a defect in the regulation of the ex-
pression of the LDLR gene or by the involvement of
another locus. This latter hypothesis was indirectly con-
firmed by other teams (Miserez and Keller 1995; Sun et
al. 1997) who reported ADH families in which they
found normal LDL-particle receptor activity and a ge-
netic exclusion of the LDLR and APOB genes. Fur-
thermore, several cases of pseudohomozygous type IIa
hypercholesterolemia have been reported by Masana et
al. (1990), who showed that probands of this rare au-
tosomal recessive hypercholesterolemia (ARH) have nor-
mal levels of LDL particles and normal LDL-particle
receptor activity. In the present study we found 13 fam-
ilies that not only support these observations but also
give evidence for the existence of a third gene involved
in ADH, which we named “FH3.” To identify FH3, we
performed linkage analyses and exclusion mapping in a
large French ADH family in which defects in LDLR or
APOB have been conclusively ruled out. After positive
LOD scores were obtained, confirmation of linkage in
this first stage was sought in a second sample of 12 ADH
families originating from France, Austria, Spain, Bel-
gium, and New Zealand and presenting the typical ADH
phenotype. Two Sardinian ARH families were also
tested.
Families and Methods
Families and Clinical Evaluation
Family HC2 is a large ADH pedigree comprising three
generations (fig. 1). All affected members were charac-
terized by levels of total cholesterol above the 97.5th
percentile when compared with other French indivud-
uals matched by age and sex (Steinmetz 1990). The pro-
band (II-9) is a 36-year-old woman, ascertained at age
17 years with 3.32 g/l total cholesterol, 2.36 g/l LDL
cholesterol, 0.48 g/l HDL cholesterol, 0.61 g/l triglyc-
erides, and arcus corneae. Her sister (II-7) is a 40-year-
old woman ascertained at age 20 years with 4.10 g/l
total cholesterol, 3.12 g/l LDL cholesterol, 0.52 g/l HDL
cholesterol, 0.75 g/l triglycerides, and arcus corneae, ten-
don xanthomas, and xanthelasmas. Distribution of total
and LDL cholesterol values in all tested HC2 members
is bimodal, indicating the autosomal dominant trans-
mission of the disease (data not shown). All lipid values
were confirmed with at least a second lipid measurement.
Among the 39 family members, seven (II-3, III-3, III-4,
III-5, III-6, II-13, and III-15) were scored as “unknown”
in linkage analyses because they presented with border-
line lipid values or because only one lipid determination
was available. In the second set of families, all affected
subjects were scored according to their level of total or
LDL cholesterol above the 95th percentile when com-
pared with other individuals from their origin popula-
tion matched by age and sex (Civeira et al. 1990; Mo-
reda et al. 1990; Williams et al. 1993). Affected subjects
( ) had mean lipid values as follows: 3.02 0.81n  46
g/l total cholesterol, 2.25  0.76 g/l LDL cholesterol,
0.52  0.19 g/l HDL cholesterol, and 1.23  0.51 g/l
triglycerides. Unaffected subjects ( ) had meann  54
lipid values as follows: 2.04 0.27 g/l total cholesterol,
1.32  0.27 g/l LDL cholesterol, 0.52 0.12 g/l HDL
cholesterol, and 0.88  0.36 g/l triglycerides. Subjects
with an unknown phenotypic status ( ) had the fol-n  6
lowing mean lipid values: 2.86  0.33 g/l total choles-
terol, 1.94  0.27 g/l LDL cholesterol, 0.52  0.10 g/
l HDL cholesterol, and 1.46 0.83 g/l triglycerides. All
these values were confirmed with at least a second lipid
measurement. Finally, in the Sardinian ARH families,
the four affected subjects presented an elevated level of
total (14 g/l) and LDL (13.5 g/l) cholesterol, and normal
triglyceride (!1.5 g/l) and HDL (!0.5 g/l) levels. All sub-
jects gave informed consent.
DNA Analysis and PCR Amplifications
DNA was isolated from whole blood samples with
use of a method described by Collod et al. (1994). PCR
amplifications and electrophoresis were performed un-
der conditions reported by Collod et al. (1994) or
adapted from Reed et al. (1994) by use of fluorescent-
labeled primers. Alleles observed in the pedigrees were
numbered arbitrarily for each marker. All marker-typing
data were collected blindly and independently by two
investigators (M.V. and J.P.R.), and all linked 1p markers
were typed twice. Nonpaternity/nonmaternity was ruled
out indirectly because no incompatible phase was found
with the numerous highly polymorphic markers tested.
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Figure 1 Segregation of chromosome 1p34.1-p32 markers in the French family HC2. Lipid values given under each family-member symbol
are (top to bottom): age at lipid measurement; levels of total, LDL, and HDL cholesterol (in grams per liter); levels of triglycerides (in grams
per liter); and apoE genotype (INNO-LiPA ApoE, Innogenetics, Murex, Chaˆtillon) (Harrington et al. 1994). Haplotypes (top to bottom) at tel-
D1S255-D1S472-D1S2892-D1S2722-D1S211-D1S197-cen markers are shown for each family member tested. Half-blackened symbols indicate
affected members, unblackened symbols indicate unaffected members, and hatched symbols indicate members with an unknown phenotypic
status. The haplotype in brackets of subject I-1 was unequivocally deduced. The common region segregating with the disease phenotype in the
family is boxed.
Parametric Linkage Analysis
Pairwise and multipoint linkage analyses were per-
formed with SLINK, MLINK, and LINKMAP of the
LINKAGE package (Ott 1991) and the VITESSE algo-
rithm (O’Connell and Weeks 1995), with the assumption
that ADH is an autosomal dominant disease with a gene
frequency of .002. Marker-allele frequencies were cal-
culated with the data from the unrelated family mem-
bers. Linkage was investigated with the assumption of
equal female-to-male recombination rates. The distances
between markers used in the LINKMAP analyses were
estimated from family data. We assumed the penetrance
for disease carriers to be .9, knowing that complete pen-
etrance can lead to false exclusion and that reduced pen-
etrance has been reported in FH and FDB. Penetrance
for noncarriers was assumed to be zero. EXCLUDE (Ed-
wards 1987) was used to produce the exclusion map.
This program estimates the positional likelihood of the
disease locus on each chromosome and the percentage
of probability of the disease locus to be on any of the
22 autosomes. Heterogeneity tests were performed with
HOMOG (Ott 1983), which computes likelihoods of
linkage under genetic heterogeneity by estimating re-
combination fractions (v) and the proportion of families
showing linkage to the markers under study (a).
Nonparametric Linkage Analysis
GENEHUNTER (Kruglyak et al. 1996) performs
complete multipoint analysis to infer the degree of iden-
tity-by-descent sharing among all affected family mem-
bers at each map point. We used the modified version
of this program, GENEHUNTER-PLUS (Kong and Cox
1997), which has been shown to be less conservative,
particularly when data are less than perfectly informa-
tive. GENEHUNTER-PLUS calculates a semiparametric
LOD score (ghpLS) by using a single parameter that is
a measure of the inheritance vector in the pedigree and
allele sharing.
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Table 1
Description of the FH3 Families Studied
FAMILY ORIGIN
NO. OF SUBJECTS WITH STATUS
LOD SCORE
AT
MUTATION
SCREENING IN
REFERENCE
POPULATIONAffected Unaffected Unknown
LDL
RECEPTOR ACTIVITYa LDLR APOBa LDLRa APOBb
HC2 France 6 25 7 Normal 6.38  4.47 nd Negative Steinmetz et al. 1990
HC67 France 4 2 0 nd 2.75 .56 nd Negative Steinmetz et al. 1990
A1 Austria 3 5 3 nd 1.88 .19 Negativec Negative Williams et al. 1993
S150 Spain 3 3 0 nd 1.18 3.79 nd Negative Moreda et al. 1990;
Civeira et al. 1990
S108 Spain 3 4 0 nd 3.53 .82 nd Negative Moreda et al. 1990;
Civeira et al. 1990
S113 Spain 4 4 0 nd 1.98 3.26 nd Negative Moreda et al. 1990;
Civeira et al. 1990
S517 Spain 4 1 0 nd .19 1.73 Negative Negative Moreda et al. 1990;
Civeira et al. 1990
S509 Spain 4 2 0 nd 1.72 1.72 nd Negative Moreda et al. 1990;
Civeira et al. 1990
S601 Spain 5 4 0 nd 2.41 .30 nd Negative Moreda et al. 1990;
Civeira et al. 1990
S129 Spain 4 0 0 nd 1.50 1.61 nd Negative Moreda et al. 1990;
Civeira et al. 1990.
S206 Spain 4 9 1 nd 4.53 2.74 nd Negative Moreda et al. 1990;
Civeira et al. 1990
B1 Belgium 6 7 0 nd 4.67 .88 nd Negative Williams et al. 1993
NZ1 N. Zealand 2 3 2 Normal .25 .66 Negative Negative Williams et al. 1993
I3 Sardinia 2 5 1 nd  nd nd Negative Williams et al. 1993
I4 Sardinia 2 10 4 nd  nd nd Negative Williams et al. 1993
a nd  not determined.
b R3500Q and R3531C.
c Promoter sequence not investigated.
Candidate Gene Mapping
We used the Radiation Hybrid Mapping Panel GENE-
BRIDGE 4 and performed PCR according to the pro-
tocol described by the supplier (Whitehead Institute/MIT
Center for Genome Research [WI/MIT]). The primers
used to test the candidate genes were reported for SCP2
(He et al. 1991), EPS15 (Genome Database; STS SHGC-
14865), and FABP3 (Phelan et al. 1996). Original prim-
ers designed in the 3′ region of the APOER2 gene were
forward, 5′-TTCTTGGCTTTGGCGAAGGTC-3′ and
reverse, 5′-TTGGGCTGATCTGGAAACGTC-3′.
Results
We have identified a large French family (HC2) in
which linkage to either LDLR or APOB was conclu-
sively excluded. In this family, 22 meioses are investi-
gated. Linkage analysis with LDLR gene markers iden-
tified two recombinants (one affected subject and one
unaffected subject). Linkage to APOB was excluded be-
cause seven recombinants were identified (two affected
subjects and five unaffected subjects). This result was
confirmed by a functional test that showed normal bind-
ing, internalization, and degradation of control LDL
particles in fibroblasts from the proband (data not
shown). Furthermore, no family member carried either
of the two most frequent hypercholesterolemic APOB
gene mutations (R3500Q, R3531C; table 1). Finally, to
exclude the possibility of type IIb, III, or IV hyperlipo-
proteinemia in this family, lipid measurements were re-
peated and apolipoprotein E variants were determined
(fig. 1).
We estimated the power of the family for linkage using
SLINK (Ott 1991) assuming an autosomal dominant
trait. We found a maximum LOD score (Zmax) of 4.13
(expected average Zmax in 500 replicates was 2.16, with
34% 1 3.00) in family HC2, showing that this family
was sufficiently informative for linkage. Two hundred
four genetic markers from 22 autosomes were tested for
linkage to the FH3 locus. These (CA)n microsatellite
markers spanning the human genome were chosen on
the basis of two criteria: heterozygosity and spacing of
∼15 cM between adjacent markers (Dib et al. 1996).
Each locus was tested for linkage to the ADH phenotype
by use of MLINK (Ott 1991) and VITESSE (O’Connell
and Weeks 1995). The combined genotype data were
also analyzed with EXCLUDE (Edwards 1987): a non-
overlapping exclusion zone of 2,955 cM, correspond-
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Table 2
Pairwise LOD Scores for Chromosome 1 Markers and ADH in HC2
LOCUS DISTANCEa
LOD SCORE AT v 
Zmax vmax.00 .001 .01 .05 .10 .20 .30 .40
D1S234 ) 6.49 4.95 3.81 2.60 1.84 .99 .52 .24 .24 .40
D1S513 .15 1.05 1.06 1.09 1.16 1.17 1.03 .73 .31 1.18 .08
D1S2830 .01 1.02 1.01 .94 .70 .49 .22 .08 .01 .01 .40
D1S255 .11 2.13 2.13 2.15 2.16 2.09 1.75 1.24 .58 2.16 .05
D1S472 .02 2.13 2.14 2.15 2.16 2.09 1.75 1.24 .58 2.17 .03
D1S2892 .08 3.13 3.13 3.11 2.98 2.77 2.22 1.54 .73 3.13 .00
D1S2722 .02 3.13 3.13 3.11 2.98 2.77 2.22 1.53 .72 3.13 .00
D1S211 .04 4.52 .13 1.11 1.70 1.81 1.62 1.17 .57 1.81 .10
D1S197 .08 2.97 .86 .15 .88 1.13 1.15 .87 .43 1.19 .15
a Distance between two adjacent markers in v.
ing to 80% of the genome, was established from the
cumulative exclusion intervals for each marker. The EX-
CLUDE analysis also indicated that the most probable
position for the FH3 locus in family HC2 was on chro-
mosome 1, with a probability of 96%. In this region, a
LOD score of 2.13 at had been obtained atv  0
D1S255 (table 2). Other microsatellites were tested
aroundD1S255, and aZmax of 3.13 ( ) was obtainedv  0
at D1S2892 and D1S2722 in the HC2 family (table 1).
Multipoint linkage analyses did not provide higher LOD
scores (data not shown). As shown in figure 1, we found
a common region (D1S2892–D1S2722) that segregated
with the ADH phenotype, localizing FH3 to a 9-cM
interval at 1p34.1-p32 (GENATLAS).
To investigate the reproducibility of linkage, other
families from different countries–with 12 presenting
ADH and 2 presenting ARH–were collected through an
international collaborative effort (table 1). Markers
D1S472, D1S2892, D1S2722, and D1S211 were tested
in these families. In three families (S113, S150, and
S517) originating from northeast Spain, LOD-score val-
ues near their Zmax were obtained for these markers.
Thus, these families present a very high probability of
linkage between the disease and the FH3 locus on chro-
mosome 1 (fig. 2, table 3). In the two Sardinian ARH
families, linkage with all the markers tested was ex-
cluded (fig. 3). To investigate whether exclusion of link-
age of ADH to 1p could be a result of wrong model
specification, we performed model-free linkage analyses
by using GENEHUNTER-PLUS (Kong and Cox 1997).
Positive ghpLS scores were obtained for families HC2,
S150, S113, and S601 (data not shown). This analysis
confirmed that the FH3 nonlinked families outlined by
our parametric linkage analyses were not excluded be-
cause of misspecification of ADH inheritance mode. Fi-
nally, to estimate the proportion of families linked to
the FH3 locus on 1p, we performed an admixture test
using HOMOG (Ott 1983), in the whole sample (family
HC2 and the 12 ADH families). As shown in table 3,
the test was statistically significant with markers
D1S472, D1S2892, and D1S2722. Furthermore, the es-
timated proportion of families with linkage to the FH3
locus was ( ) at D1S2892 anda  27% P  .005 a 
( ) at D1S2722. Multipoint HOMOG25% P  .005
analysis gave a Zmax of 2.97 ( , ) be-a  25% P  .0025
tween D1S2892 and D1S2722 at fromv  .01
D1S2892.
The FH3 gene maps to 1p34.1-p32, which also har-
bors numerous genes including those that encode a sterol
carrier protein (SCP2; Ohba et al. 1994), a fatty
acid–binding protein (FABP3; Phelan et al. 1996), an
apolipoprotein E receptor (APOER2; Kim et al. 1997),
and an epidermal growth factor receptor–pathway sub-
strate (EPS15; Wong et al. 1994). To determine whether
these positional and functional candidate genes mapped
within the critical interval defined by D1S472 and
D1S211 should be further investigated, we used the
GENEBRIDGE 4 radiation hybrid panel. The results
showed that all these genes did not map within the in-
terval, excluding the possibility of identity between the
FH3 gene and one of these regional candidates (data not
shown) and suggesting a novel gene for ADH on 1p34.1-
p32.
Discussion
We located a third gene involved in ADH on chro-
mosome 1p34.2-p32 and identified a large French family
in which the involvement of either LDLR or APOB was
excluded conclusively. This result was confirmed by a
functional test that showed that fibroblasts from the pro-
band showed normal binding, internalization, and deg-
radation of control LDL particles. Furthermore, no fam-
ily member carried either of the two most frequent
hypercholesterolemic APOB gene mutations (R3500Q,
R3531C). To exclude the possibility of type IIb, III, or
IV hyperlipoproteinemia in this family, lipid measure-
ments were repeated and apolipoprotein E variants were
determined. Furthermore, linkage was also clearly ex-
cluded between the disease gene and the LPL locus on
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Figure 2 Segregation of chromosome 1p34.1-p32 markers in the Spanish families S113, S601, S150, and S517. Lipid values given under
each family-member symbol are (top to bottom): age at lipid measurement levels of total, LDL, and HDL cholesterol (in grams per liter); and
levels of triglycerides in (grams per liter). Haplotypes (top to bottom) at tel-D1S472-D1S2892-D1S2722-D1S211-cen markers are shown for
each family member tested. Half-blackened symbols indicate affected members and unblackend symbols indicate unaffected members. The
common region transmitted with the disease phenotype in each family is boxed.
chromosome 8, as well as the APOA1-C3-A4 gene clus-
ter on chromosome 11 and the 1q21-q23 region, both
of which are associated with familial combined hyper-
lipidemia (Wojciechowski et al. 1991; Pajukanta et al.
1998). Because this family was clinically and biologically
indistinguishable from FH or FDB families and the ex-
pected LOD score showed sufficient power in the ped-
igree, we used exclusion mapping to localize the disease
gene. The phenotypic status of each family member was
carefully and independently established by four research-
ers (M.D., M.K., J-P.R., and C.B.) and by other recog-
nized French experts. To avoid spurious results from
misclassification, members with borderline lipid values
were scored as “unknown” in the genetic analyses (seven
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Table 3
Pairwise LOD-Score Analyses for ADH and 1p Regional Markers
FAMILY
Zmax (v) AT MARKER
D1S472 D1S2892 D1S2722 D1S211 Zmax
a
HC2 2.16 (.05) 3.13 (0) 3.13 (0) 1.81 (.1) 4.13
HC67 .01 (.4) 0 (.4) 0 (.4) 0 (.4) .86
A1 .15 (0) .09 (.4) .02 (.4) .09 (.4) 1.01
S150 .56 (0) .82 (0) .82 (0) .82 (0) .82
S108 nd .02 (.4) .02 (.4) nd .84
S113 .07 (0) 1.34 (0) .21 (0) .2 (0) 1.35
S517 .03 (.4) 0 (.4) .64 (0) .01 (.3) .79
S509 nd 0 (.4) .01 (.4) nd .79
S601 .09 (0) .50 (.05) .07 (0) .41 (.05) 1 .61
S129 nd .02 (.4) .02 (.4) nd .75
S206 .05 (.4) .19 (.3) .01 (.4) .15 (.3) 2.46
B1 .43 (.4) .20 (.4) .2 (.4) .18 (.4) 1.94
NZ1 nd .01 (.4) 0 (.4) nd .50
Total Zmax (v) .17 (.3) 1.59 (.2) 1.04 (.2) 1.13 (.2) )
HOMOGENEITY ADMIXTURE TEXT AT MARKER
Total Zmax (v [a]) 1.43 (.1 [32%]) 2.88 (0 [27%]) 2.43 (0 [25%]) 1.45 (.01 [46%]) )
P VALUE .01 .005 .005 .11 )
POSTERIOR PROBABILITY OF LINKAGE AT MARKER
HC2 .985 .998 .998 .982 )
HC67 .155 .027 .004 .319 )
A1 .399 .004 .155 .154 )
S150 .625 .700 .688 .792 )
S108 .320 .014 .001 .460 )
S113 .351 .883 .351 .540 )
S517 .005 .096 .593 .344 )
S509 .320 .025 .002 .460 )
S601 .316 .533 .281 .676 )
S129 .320 .023 .009 .460 )
S206 .0004 .123 .035 .314 )
B1 .001 .001 .001 .032 )
NZ1 .320 .103 .155 .460 )
NOTE.—nd  not determined.
a Zmax encountered in the 500 SLINK replicates.
subjects). We chose this conservative approach despite
loss of power. In the absence of established genetic par-
ameters for this autosomal dominant disease, we as-
sumed it to be comparable to FH or FDB. Therefore,
linkage analyses were performed with a gene frequency
of .002 and penetrance of .9. At D1S2892 and
D1S2722, the Zmax exceeded the threshold of 3 in the
family ( , ; table 2), strongly supportingZ  3.13 v  0max
the hypothesis of an ADH locus at 1p. As shown in
figure 1, family data also showed an affected subject (II-
5) with a proximal recombination event, between
D1S2722 and D1S211, and an unaffected subject (III-
1) with a distal recombination event between D1S472
and D1S2892. Furthermore, all affected individuals
shared the region flanked by markers D1S2892 and
D1S2722. Together these data place FH3 in a region !9
cM, flanked by markers D1S472 and D1S211. Inter-
estingly, the subjects with no definite diagnosis (II-3, III-
3, III-4, III-5, III-6, II-13, and III-15), did not carry the
disease-associated two-marker haplotype. This obser-
vation supported our conservative approach. However,
an 8-year-old boy (III-3), with a total-cholesterol level
of 1.46 g/l and an LDL-cholesterol level of 0.72 g/l, also
carried the disease-associated region. This observation
explains why the Zmax was not reached at 1p.
In an attempt to replicate this positive linkage, we
studied a second set of 12 ADH families from various
countries (table 1). These families met the following clin-
ical and biological criteria: (1) ADH phenotype; (2) nor-
mal LDL-particle receptor activity, and/or absence of
mutations in the whole LDLR gene, and/or genetic ex-
clusion of the LDLR gene; and (3) genetic exclusion of
APOB and/or absence of mutations R3500Q and
R3531C in APOB. Phenotypic status was established
for each subject on the basis of the appropriate national
reference population. Three families (S113, S150, and
S517) gave two-point LOD scores, with D1S2892 and
D1S2722 very close to their possible Zmax (table 3), sup-
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Figure 3 Segregation of chromosome 1p34.1-p32 markers in the Sardinian families It3 and It4. Lipid values given under each family-
member symbol are (top to bottom): age at lipid measurement; levels of total, LDL, and HDL cholesterol (in grams per liter); and levels of
triglycerides (in grams per liter). Haplotypes (top to bottom) at tel-D1S2892-D1S2722-D1S211-cen markers are shown for each family member
tested. Blackened symbols indicate affected members, unblackened symbols indicate unaffected members, and hatched symbols indicate members
with an unknown phenotypic status.
porting the localization of the FH3 gene. In families S113
and S150, a common four-marker haplotype was carried
by all the affected members. Conversely, in family S517
a positive LOD score was obtained only at D1S2722,
but careful examination of family data did not show a
conserved region shared by affected members. In family
S601, LOD scores were of small value; however, all af-
fected members shared a common region. Furthermore,
this region was also shared by an unaffected 24-year-
old woman (II-9; 1.94 g/l total cholesterol and 1.29 g/l
LDL cholesterol). This observation could be compared
with that of subject III-13 of the HC2 family. It is un-
likely that both these subjects are double recombinants.
However, it is highly possible that, with the criteria used
for the classification of family members, the penetrance
of the disease gene is not complete in children and young
adults.
Admixture tests were performed on a sample com-
prising the HC2 family and the set of 12 ADH families.
The hypothesis of genetic homogeneity was rejected
against the hypothesis of heterogeneity at a significance
level of 1%. These results showed that the ADH phe-
notype is more heterogeneous than what we at first had
assumed. For the remaining ADH non-1p families, an-
other locus, named “FH4,” could be involved. We also
studied two Sardinian families displaying ARH, the rare
pseudohomozygous type IIa hypercholesterolemia dis-
ease with an autosomal recessive transmission. Despite
the different transmission modes, we thought it was pos-
sible that some mutations in the FH3 gene could give
rise to ADH and that some others could lead to ARH,
as has been reported for other diseases, such as retinitis
pigmentosa (MIM 268000). As shown in figure 3, no
allele identity was apparent between the affected sibs (II-
2 and II-3) of family It3, and identical alleles are shared
by the affected sibs (II-1 and II-4) of family It4 and their
unaffected sib (II-2). These results show that, in the two
ARH families, the disease is not linked to the FH3 gene.
In these families, the disease gene could be identical to
either the FH4 gene or another as yet unidentified gene.
Our data provide strong evidence for an additional
locus contributing to ADH and its assignment to chro-
mosome 1p34.1-p32. Positioning the disease locus in
relation to the genetic map indicates that the FH3 gene
is located within a 9-cM interval flanked by D1S472
and D1S211. These microsatellite markers map to a re-
gion that contains four candidate cloned genes, as fol-
lows: SCP2 (sterol carrier protein 2), which encodes a
lipid transport basic protein believed to facilitate the
movement of cholesterol and phospholipids within the
cell (Ohba et al. 1994); MDGI/FABP3 (mammary-de-
rived growth inhibitor/fatty acid–binding protein 3-mus-
cle and heart), which encodes a protein that transports
vehicles of hydrophobic fatty acids throughout the cy-
toplasm and is a candidate tumor-suppressor gene for
human breast cancer, although no mutation in this gene
has been reported in sporadic breast tumors (Phelan et
al. 1996); APOER2 (apolipoprotein E receptor 2),
which encodes a receptor that resembles LDL and very-
low-density lipoprotein receptors and is most highly ex-
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pressed in human brain and placenta (Kim et al. 1997);
and EPS15 (epidermal growth factor receptor path-
way–substrate), which encodes a protein that is impli-
cated in the receptor-mediated endocytosis pathway
(Wong et al. 1994). To clarify the positional relationship
between these regional candidate genes and the markers
linked to the FH3 gene, we mapped them relative to the
WI/MIT radiation hybrid map. The results showed that
all these candidate genes are not located within the
D1S472–D1S211 interval, excluding possible identity
between the FH3 gene and one of these candidates and
suggesting a novel gene for ADH on 1p34.1-p32.
To conclude, the 13 families we have identified give
evidence for the existence of a greater level of genetic
heterogeneity than conventionally has been assumed for
ADH. Our results indirectly show that FH3 encodes a
protein, as yet unknown, whose function is important
in the control of cholesterol homeostasis. Defects in this
new pathway could explain the resistance to drug ther-
apy observed among some patients with hypercholes-
terolemia. The identification of the FH3 gene may help
to develop new intervention strategies to limit elevation
of LDL particles and prevent morbidity and mortality
from premature atherosclerosis.
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